Abstract | BACKGROUND: METHOD: We purified Cuc IIa, the active component from the medicinal plant Hemsleya amalils Diels, which shows different structural modifications from other Cuc derivatives. We investigated the mechanisms of its inhibitory effects on cancer cells in vitro and tumour growth in vivo. RESULTS: CONCLUSION:
Cuc IIa is a novel class of anti- cancer drug in suppression of cancer cell expansion by disrupting the actin cytoskeleton and directing the cell to undergo PARP-mediated apoptosis through the inhibition of survivin downstream of JAK2/STAT3.
|
Authors | C Boykin, G Zhang, Y-H Chen, R-W Zhang, X-E Fan, W-M Yang, Q Lu |
Journal | British journal of cancer
(Br J Cancer)
Vol. 104
Issue 5
Pg. 781-9
(Mar 01 2011)
ISSN: 1532-1827 [Electronic] England |
PMID | 21304528
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Actins
- Antineoplastic Agents
- BIRC5 protein, human
- Birc5 protein, mouse
- Inhibitor of Apoptosis Proteins
- Microtubule-Associated Proteins
- Repressor Proteins
- STAT3 Transcription Factor
- Survivin
- cucurbitacin IIa
- Cucurbitacins
- JAK2 protein, human
- Jak2 protein, mouse
- Janus Kinase 2
|
Topics |
- Actins
(metabolism)
- Animals
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Cell Line, Tumor
- Cucurbitacins
(pharmacology, therapeutic use)
- Humans
- Inhibitor of Apoptosis Proteins
(metabolism)
- Janus Kinase 2
(metabolism)
- Mice
- Microtubule-Associated Proteins
(metabolism)
- Phosphorylation
- Repressor Proteins
(metabolism)
- STAT3 Transcription Factor
(metabolism)
- Signal Transduction
- Survivin
|